Woonsocket, Rhode Island-based CVS Health Corporation (CVS) offers a comprehensive range of healthcare solutions, including pharmacy benefit management services, mail-order pharmacies, retail pharmacies, specialty pharmacies, disease management programs, and retail clinics. Valued at a market cap of $80.7 billion, the company combines clinical expertise, technology, and personalized care to deliver comprehensive health solutions that support better health outcomes and long-term wellness. It is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Jul. 31.

Before this event, analysts project this healthcare solutions provider to report a profit of $1.47 per share, down 19.7% from $1.83 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $2.25 per share in the previous quarter topped the consensus estimates by a notable margin of 31.6%. 

For the full year, analysts expect CVS to report EPS of $6.12, up 12.9% from $5.42 in fiscal 2024. Its EPS is expected to further grow 14.4% year-over-year to $7 in fiscal 2026. 

CVS has gained 6.2% over the past 52 weeks, underperforming the S&P 500 Index's ($SPX) 10.5% return over the same time frame. However, it has outpaced the Health Care Select Sector SPDR Fund’s (XLV) 10.4% loss over the same period.

On May 1, shares of CVS observed a 4.1% rise after the company reported better-than-expected Q1 results. Its overall revenue improved 7% year-over-year to $94.6 billion, topping the consensus estimates by 1.8%. Moreover, its adjusted EPS of $2.25 advanced 71.8% from the year-ago quarter, exceeding the analyst estimates by a notable margin of 31.6%. Robust revenue and adjusted operating income growth across all of its reportable segments aided its quarterly results. Additionally, CVS raised its fiscal 2025 adjusted EPS guidance in the range of $6 to $6.20, reflecting strong performance across each of its businesses. 

Wall Street analysts are highly optimistic about CVS’ stock, with a "Strong Buy" rating overall. Among 23 analysts covering the stock, 17 recommend "Strong Buy," two indicate "Moderate Buy," and four suggest "Hold.” The mean price target for CVS is $79.55, implying a 24.7% premium from the current levels.